Carlos Ortuño-Pineda

Carlos Ortuño-Pineda

Auto-generated profile, based on publicly available information

Carlos Ortuño-Pineda

Universidad Autónoma de Guerrero

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MOMonserrat Olea-Flores
Monserrat Olea-Flores
MZMiriam Zuñiga-Eulogio
Miriam Zuñiga-Eulogio
Miguel Mendoza-CatalánMiguel Mendoza-Catalán
Miguel Mendoza-Catalán
HRHugo Alberto Rodríguez Ruiz
Hugo Alberto Rodríguez Ruiz
ECEduardo Castañeda-Saucedo
Eduardo Castañeda-Saucedo
Napoleón Navarro-TitoNapoleón Navarro-Tito
Napoleón Navarro-Tito
Epithelial–mesenchymal transition (EMT) is a reversible cellular process, characterized by changes in gene expression and activation of proteins, favoring the trans-differentiation of the epithelial phenotype to a mesenchymal phenotype. This process increases cell migration and invasion of tumor cells, progression of the cell cycle, and resistance to apoptosis and chemotherapy, all of which support tumor progression. One of the signaling pathways involved in tumor progression is the MAPK pathway. Within this family, the ERK subfamily of proteins is known for its contributions to EMT. The ERK subfamily is divided into typical (ERK 1/2/5), and atypical (ERK 3/4/7/8) members. These kinases are overexpressed and hyperactive in various types of cancer. They regulate diverse cellular processes such as proliferation, migration, metastasis, resistance to chemotherapy, and EMT. In this context, in vitro and in vivo assays, as well as studies in human patients, have shown that ERK favors the expression, function, and subcellular relocalization of various proteins that regulate EMT, thus promoting tumor progression. In this review, we discuss the mechanistic roles of the ERK subfamily members in EMT and tumor progression in diverse biological systems.

15 March 2021 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
LSLorena Cayetano Salazar
Lorena Cayetano Salazar
MOMonserrat Olea-Flores
Monserrat Olea-Flores
MZMiriam Zuñiga-Eulogio
Miriam Zuñiga-Eulogio
CWCaroline Weinstein‐Oppenheimer
Caroline Weinstein‐Oppenheimer
GFGloria Fernández-Tilapa
Gloria Fernández-Tilapa
Napoleón Navarro-TitoNapoleón Navarro-Tito
Napoleón Navarro-Tito

15 December 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
MOMonserrat Olea-Flores
Monserrat Olea-Flores
JCJUAN CARLOS CRUZ
JUAN CARLOS CRUZ
MZMiriam Zuñiga-Eulogio
Miriam Zuñiga-Eulogio
ECErika Jaqueline Acosta De la Cruz
Erika Jaqueline Acosta De la Cruz
EGEduardo García-Rodríguez
Eduardo García-Rodríguez
Napoleón Navarro-TitoNapoleón Navarro-Tito
Napoleón Navarro-Tito
Leptin is a hormone secreted mainly by adipocytes; physiologically, it participates in the control of appetite and energy expenditure. However, it has also been linked to tumor progression in different epithelial cancers. In this review, we describe the effect of leptin on epithelial–mesenchymal transition (EMT) markers in different study models, including in vitro, in vivo, and patient studies and in various types of cancer, including breast, prostate, lung, and ovarian cancer. The different studies report that leptin promotes the expression of mesenchymal markers and a decrease in epithelial markers, in addition to promoting EMT-related processes such as cell migration and invasion and poor prognosis in patients with cancer. Finally, we report that leptin has the greatest biological relevance in EMT and tumor progression in breast, lung, prostate, esophageal, and ovarian cancer. This relationship could be due to the key role played by the enriched tumor microenvironment in adipose tissue. Together, these findings demonstrate that leptin is a key biomolecule that drives EMT and metastasis in cancer.

27 March 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
AGAna Elvira Zacapala Gómez
Ana Elvira Zacapala Gómez
Napoleón Navarro-TitoNapoleón Navarro-Tito
Napoleón Navarro-Tito
LALuz del Carmen Alarcón-Romero
Luz del Carmen Alarcón-Romero
COCarlos Ortuño-Pineda
Carlos Ortuño-Pineda
BIBerenice Illades-Aguiar
Berenice Illades-Aguiar
Miguel Mendoza-CatalánMiguel Mendoza-Catalán
Miguel Mendoza-Catalán
Cervical cancer (CC) is the fourth cause of mortality by neoplasia in women worldwide. The use of immunomarkers is an alternative tool to complement currently used algorithms for detection of cancer, and to improve selection of therapeutic schemes. Aberrant expression of Ezrin and E-cadherin play an important role in tumor invasion. In this study we analyzed Ezrin and E-cadherin expression in liquid-based cervical cytology samples, and evaluated their potential use as prognostic immunomarkers. Immunocytochemical staining of Ezrin and E-cadherin was performed in cervical samples of 125 patients. The cytological or histological diagnostic was performed by Papanicolaou staining or H&E staining, respectively. HPV genotyping was determined using INNO-LIPA Genotyping Extra kit and the HPV physical status by in situ hybridization. Ezrin expression in HaCaT, HeLa and SiHa cell lines was determined by immunocytochemistry, immunofluorescence and Western blot. High Ezrin expression was observed in cervical cancer samples (70%), samples with multiple infection by HR-HPV (43%), and samples with integrated viral genome (47%). High Ezrin expression was associated with degree of SIL, viral genotype and physical status. In contrast, low E-cadherin expression was found in cervical cancer samples (95%), samples with multiple infection by HR-HPV/LR-HPV (87%) and integrated viral genome (72%). Low E-cadherin expression was associated with degree of SIL and viral genotype. Interestingly, Ezrin nuclear staining was associated with degree of SIL and viral genotype. High Ezrin expression, high percent of nuclear Ezrin and low E-cadherin expression behaved as risk factors for progression to HSIL and cervical cancer. Ezrin and E-cadherin expression profile in cervical cytology samples could be a potential prognostic marker, useful for identifying cervical lesions with a high-risk of progression to cervical cancer.

23 February 2022 in Journal of Mammary Gland Biology and Neoplasia
Verified
Journal Article
Closed access
PDF file
JCJUAN CARLOS CRUZ
JUAN CARLOS CRUZ
MOMichal Okoniewski
Michal Okoniewski
MRMonica Ramirez
Monica Ramirez
COCarlos Ortuño-Pineda
Carlos Ortuño-Pineda
Napoleón Navarro-TitoNapoleón Navarro-Tito
Napoleón Navarro-Tito
ECEduardo Castañeda-Saucedo
Eduardo Castañeda-Saucedo

8 May 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
JCJUAN CARLOS CRUZ
JUAN CARLOS CRUZ
MZMiriam Zuñiga-Eulogio
Miriam Zuñiga-Eulogio
MOMonserrat Olea-Flores
Monserrat Olea-Flores
ECEduardo Castañeda-Saucedo
Eduardo Castañeda-Saucedo
Miguel Mendoza-CatalánMiguel Mendoza-Catalán
Miguel Mendoza-Catalán
Napoleón Navarro-TitoNapoleón Navarro-Tito
Napoleón Navarro-Tito
Breast cancer is the most common invasive neoplasia, and the second leading cause of death associated with cancer in women worldwide. Mammary tumorigenesis is severely linked to obesity, the potential connection is leptin. Leptin is a hormone secreted by adipocytes, which contributes to the progression of breast cancer. Cell migration, metalloproteases secretion, and invasion are cellular processes associated with various stages of metastasis. These processes are regulated by the kinases FAK and Src. In this study, we utilized the breast cancer cell lines MCF7 and MDA-MB-231 to determine the effect of leptin on FAK and Src kinases activation, cell migration, metalloproteases secretion, and invasion. By Western blot we found that leptin activates FAK and Src, and induces the localization of FAK to the focal adhesions. Specific inhibitors of FAK and Src showed that the effect exerted by leptin in cell migration, and invasion in breast cancer cells is dependent on these kinases. Moreover, by gelatin zymmography we established that leptin promotes the secretion of the extracellular matrix remodelers, MMP-2 and MMP-9, in a FAK and Src dependent manner. Our findings strongly suggest that leptin promotes the development of a more aggressive invasive phenotype in mammary cancer cells.